Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04875286 · ClinicalTrials.gov registry record

Patient Reported Symptom Control With THC or CBD Use

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
200
Enrollment target
2
Study locations

NCT04875286: Active study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

NCT04875286 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04875286, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
200 participants
Enrollment target
2
Study locations

Study Summary

This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related symptoms.

Primary Outcome

Will be calculated and reported along with a 95% confidence interval.

Interventions

  • OTHER Questionnaire Administration
  • OTHER Electronic Health Record Review

Study Locations (2)

Arizona

  • Banner MD Anderson Cancer Center - Gilbert

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-02-03
Est. Completion 2027-02-02
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT04875286 still lists

NCT04875286 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (82% lower).

The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.

NCT04875286 reports a single indexed study location in Arizona, Texas.

Frequently Asked Questions

What is clinical trial NCT04875286 about?

NCT04875286 is a clinical study titled "Patient Reported Symptom Control With THC or CBD Use". This study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. This study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common can...

What is the current status of trial NCT04875286?

This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2021-02-03. Estimated completion is 2027-02-02.

What conditions does trial NCT04875286 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Cancer Associated Pain.

What interventions are being tested in trial NCT04875286?

The interventions under investigation include: Questionnaire Administration (OTHER), Electronic Health Record Review (OTHER).

Who is sponsoring clinical trial NCT04875286?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04875286 being conducted?

This trial has 2 study locations across Arizona, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04875286's enrollment target sits among peer trials

200 61st of 176 higher than 109 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04875286, the US trial registry maintained by the National Library of Medicine. NCT04875286 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.